# Bortezomib-Dexamethasone-Doxorubicin-Study

> **NCT00401804** · PHASE2 · COMPLETED · sponsor: **Austrian Forum Against Cancer** · enrollment: 72 (actual)

## Conditions studied

- Multiple Myeloma
- Renal Insuficiency

## Interventions

- **DRUG:** Dexamethasone, Bortezomib, Doxorubicin

## Key facts

- **NCT ID:** NCT00401804
- **Lead sponsor:** Austrian Forum Against Cancer
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2008-11
- **Final completion:** 2009-11
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2013-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00401804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00401804, "Bortezomib-Dexamethasone-Doxorubicin-Study". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00401804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*